Skip to main content

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Cartesian Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of RNAC: Q3 2025 compared with Q4 2025
MeasureQ3 2025Q4 2025Change
Holders6867−1
Shares5.99M5.16M−832.5K (−13.9%)
Value$60.9M$37.2M−$23.7M (−38.9%)

New holders (15)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to RNAC in Q4 2025
InstitutionSharesValue% of portfolio
Privium Fund Management B.V.172,500$1.24M0.23%
Two Sigma Investments, LP91,278$658.1K0.00%
Walleye Capital LLC43,878$316.4K0.00%
Renaissance Technologies LLC41,100$296.3K0.00%
Point72 Asset Management, L.P.33,871$244.2K0.00%
Two Sigma Advisers, LP24,808$178.9K0.00%
Ameriprise Financial Inc19,806$142.8K0.00%
Squarepoint Ops LLC18,213$131.3K0.00%
Jain Global LLC16,724$120.6K0.00%
Public Employees Retirement System of Ohio15,500$111.8K0.00%
R Squared Ltd10,308$74.3K0.03%
UBS Asset Management Americas Inc516$3.72K0.00%
Jones Financial Companies LLLP200$1.44K0.00%
The PNC Financial Services Group, Inc.5$360.00%
SageView Advisory Group, LLC3$220.00%

Sold out (16)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.